Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia
NCT06488794Phase 3Not yet recruiting
- Sponsor
- Fattouma Bourguiba University Hospital
- Start
- Jan 2027
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of colistimethate sodium in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Fattouma Bourguiba University Hospital. Primary endpoint: Incidence of Ventilation Associated Pneumonia at 28 days. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
colistimethate sodium
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT06488794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488794.